Bio-Techne (TECH) Institutional Ownership 2025 - MarketBeat

102 rows · 6 days ago · Of the 286 institutional investors that sold Bio-Techne stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: …

2%
OFF

Bio-Techne Co. (NASDAQ:TECH) Shares Sold By Truist Financial Corp

2 weeks from now

Oct 13, 2024 · Truist Financial Corp decreased its stake in Bio-Techne Co. (NASDAQ:TECH – Free Report) by 2.2% in the 2nd quarter, according to the company in its most recent filing …

etfdailynews.com

$7068800.00
OFF

Bio-Techne (TECH) Insider Trading Activity 2025 - MarketBeat

2 weeks from now

3 days ago · The following insiders have sold TECH shares in the last 24 months: Charles R Kummeth ($7,068,800.00), and Roeland Nusse ($1,518,572.48). How much insider selling is …

marketbeat.com

$0.42
OFF

Bio-Techne (TECH) Stock Price, News & Analysis - MarketBeat

2 weeks from now

6 days ago · Bio-Techne Co. (NASDAQ:TECH) announced its earnings results on Wednesday, October, 30th. The biotechnology company reported $0.42 EPS for the quarter, beating …

marketbeat.com

97%
OFF

Bio-Techne Corporation (TECH) - Stock Analysis

2 weeks from now

Jan 8, 2025 · Financial Performance. In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. ... Bio-Techne Corporation …

stockanalysis.com

$75.27
OFF

Stifel Financial Corp Acquires 3,731 Shares Of Bio-Techne Co.

2 weeks from now

Dec 18, 2024 · View Our Latest Stock Report on TECH. Bio-Techne Trading Down 1.2 %. NASDAQ:TECH opened at $75.27 on Wednesday. The stock has a market cap of $11.96 …

etfdailynews.com

6%
OFF

Bio-Techne Corporation (NASDAQ:TECH) Stock's Been Sliding But ...

2 weeks from now

Nov 25, 2021 · With its stock down 6.6% over the past month, it is easy to disregard Bio-Techne (NASDAQ:TECH). However, stock prices are usually driven by a company’s financials over …

nasdaq.com

FAQs about Bio-Techne (TECH) Institutional Ownership 2025 - MarketBeat Coupon?

Did Truist Financial reduce its stake in Bio-Techne co?

Truist Financial Corp decreased its stake in Bio-Techne Co. (NASDAQ:TECH – Free Report) by 2.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,360 shares of the biotechnology company’s stock after selling 479 shares during the period. ...

How much is Truist Financial Corp's Bio-Techne stock worth?

Truist Financial Corp’s holdings in Bio-Techne were worth $1,530,000 at the end of the most recent reporting period. A number of other hedge funds have also recently modified their holdings of the stock. First City Capital Management Inc. increased its position in Bio-Techne by 6.2% during the first quarter. ...

Should you buy Bio-Techne (tech) stock in 2024?

In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%. According to 8 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $82.0, which is an increase of 14.72% from the latest price. ...

Will Bio-Techne Corporation (tech) stock cap a solid 2024?

The stock market rallied in November and December of 2016 and 2020 post-election, and investors are hoping for more of the same to cap a solid 2024 for stocks. Find the latest Bio-Techne Corporation (TECH) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

Who owns Bio-Techne stock?

Bio-Techne's stock is owned by a number of retail and institutional investors. Top institutional investors include Select Equity Group L.P. (4.55%), Bamco Inc. NY (3.51%), Neuberger Berman Group LLC (2.63%), Geode Capital Management LLC (2.34%), Winslow Capital Management LLC (2.00%) and Morgan Stanley (1.90%). ...

Is Bio-Techne (bio) a great stock to buy?

Bio-Techne has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. ...